NEWS
Online rush helps Keypath beat revenues forecast during float
MELBOURNE: Booming demand for courses in nursing and allied health and the “normalisation” ... read more
Mesoblast could need another COVID trial says CEO
MELBOURNE: Losses at stem cell treatments producer Mesoblast have hit $US98.8 million ($135 ... read more
Healius eyes M&A after sales surge says CEO
MELBOURNE: Healius boss Malcolm Parmenter says the healthcare giant is seeking to make ... read more
Regis Healthcare set to reinstate final dividend
MELBOURNE: Regis Healthcare has reinstated its final dividend despite a host of issues ... read more
